VTP-600 / Barinthus Bio, Ludwig Institute for Cancer Research, Cancer Research UK - LARVOL DELTA

CRUKD/20/001: A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1 (clinicaltrials.gov) - P1/2 | N=15 | Suspended | Sponsor: Cancer Research UK | Trial completion date: Mar 2029 ➔ Oct 2026

Checkpoint inhibition • First-in-human • Trial completion date • Esophageal Cancer • Esophagogastric Junction Squamous Cell Carcinoma • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • MAGEA3 • PD-L1

Preliminary peripheral immunogenicity of a MAGE-A3/NY-ESO-1 viral vector vaccine with chemo-immunotherapy in NSCLC (ESMO-IO 2025) - P1/2 | "Background The MAGE trial (NCT04908111) is a phase I/IIa study of VTP-600 (a heterologous ChAdOx1 & MVA viral vector vaccine, encoding MAGE-A3/NY-ESO-1) administered with first-line standard-of-care (SoC) pembrolizumab plus platinum-doublet chemotherapy in advanced NSCLC. Tregs and total MDSC were present in both arms with variable kinetics: Tregs increased around C3D15 and MDSC around C4D8 in the vaccine arm, with both returning towards baseline by end of treatment.Conclusions When initiated at C3D1 of chemo-immunotherapy, VTP-600 was associated with low peripheral antigen-specific T-cell responses by ELISpot and with peripheral immune features that may be unfavourable for vaccine activity, suggesting that this schedule may be suboptimal, potentially due to the timing vs the chemotherapy or its co-administered steroid. For combination therapy, evaluating vaccination timing relative to SoC is likely to be important and cannot necessarily be predicted..."

IO biomarker • Viral vector • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CTAG1B • HAVCR2 • LAMP1 • MAGEA3 • PD-1

CRUKD/20/001: A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1 (clinicaltrials.gov) - P1/2 | N=15 | Suspended | Sponsor: Cancer Research UK | Trial completion date: Oct 2026 ➔ Mar 2029

Checkpoint inhibition • Trial completion date • Esophageal Cancer • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • MAGEA3 • PD-L1

A phase I/IIa trial of ChAdOx1 and MVA vaccines against MAGE-A3 and NY-ESO-1 (ESMO 2023) - P1/2 | "Trial design This is a multi-centre, first-in-human, phase I/IIa, randomised, open label trial, run in the UK, for patients scheduled to receive first-line chemo-immunotherapy containing pembrolizumab as standard of care (SoC) treatment, for Stage III/IV NSCLC (and potentially additional indications) expressing MAGE-A3 +/- NYESO-1 (NCT04908111)...The primary objective is safety and tolerability, with key secondary objectives of immunogenicity and clinical efficacy. Tertiary objectives include correlative translational analyses."

P1/2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CTAG1B • MAGEA3

Cancer Research UK Dose First Patient in Phase I/IIa Trial of Lung Cancer Immunotherapy Vaccine (GlobeNewswire) - "Cancer Research UK, Vaccitech plc (Nasdaq: VACC) and the Ludwig Institute for Cancer Research (Ludwig), today announce the first patient dosed in the MAGE trial, which is testing a novel immunotherapeutic, VTP-600, in patients with the most common type of lung cancer. The phase I/IIa trial is expected to enroll approximately 86 people who have been newly diagnosed with non-small cell lung cancer (NSCLC) and will be testing the safety and initial efficacy of VTP-600 in these patients. VTP-600 will be given in combination with the current first line treatment for NSCLC...The trial is expected to run over 2-3 years."

Trial status • Lung Cancer • Non Small Cell Lung Cancer • Oncology

Vaccitech Reports Third Quarter 2021 Financial Results and Recent Corporate Developments (GlobeNewswire) - "In the fourth quarter, the Company expects to initiate dosing in a Phase 1/2a trial of VTP-600 in patients with non-small cell lung cancer in combination with a checkpoint inhibitor and chemotherapy. The trial is currently open for enrollment; In the second quarter of 2022, the Company expects to initiate dosing in a Phase 1/2a clinical trial of VTP-800/850, in combination with a checkpoint inhibitor, in patients with prostate cancer."

New P1/2 trial • Non Small Cell Lung Cancer • Oncology • Prostate Cancer

A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1 (clinicaltrials.gov) - P1/2; N=86; Recruiting; Sponsor: Cancer Research UK; Not yet recruiting ➔ Recruiting

Checkpoint inhibition • Enrollment open • Immune Modulation • Inflammation • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • MAGEA3 • PD-L1

A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1 (clinicaltrials.gov) - P1/2; N=86; Not yet recruiting; Sponsor: Cancer Research UK; Initiation date: May 2021 ➔ Sep 2021

Checkpoint inhibition • Trial initiation date • Immune Modulation • Inflammation • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • MAGEA3 • PD-L1

Vaccitech Reports Second Quarter 2021 Financial Results and Recent Corporate Developments (GlobeNewswire) - "In the fourth quarter of 2021...the Company expects to initiate dosing in the Phase 1/2a trial of VTP-600 in patients with non-small cell lung cancer in combination with a checkpoint inhibitor and chemotherapy."

Trial status • Lung Cancer • Non Small Cell Lung Cancer • Oncology

A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1 (clinicaltrials.gov) - P1/2; N=86; Not yet recruiting; Sponsor: Cancer Research UK

Checkpoint inhibition • New P1/2 trial • Immune Modulation • Inflammation • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • MAGEA3 • PD-L1